InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,731.78
(
-0.10%
)
Post# of 251790
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 177462

Wednesday, 08/20/2014 5:58:53 PM

Wednesday, August 20, 2014 5:58:53 PM

Post# of 251790
ARRY’s 2Q14 PR says ARRY expects NVS to return MEK162 as a consequence of NVS’ acquisition of GSK’s oncology portfolio (which includes Mekinst):

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1957741&highlight

Array planning for potential return of binimetinib… In April 2014, Novartis and GlaxoSmithKline (GSK) announced a definitive agreement which included Novartis acquiring GSK's MEK inhibitor, Mekinist. The transaction is subject to approval by GSK shareholders and closing conditions, including anti-trust approvals. If Novartis' binimetinib development and commercialization rights are returned to Array, Novartis must provide support for ongoing clinical studies as specified in our agreement.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up